AVTX vs IT · P/E 0.0, rev $441.0K vs P/E 16, rev $6.27B
Avalo Therapeutics Inc (AVTX) versus Gartner Inc (IT) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Gartner Inc (IT) is a information technology services company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Not investment advice. Open the AVTX and IT stock pages for the full models.
Not investment advice.